| Year ended 31 March 2026 £000 | Year ended 31 March 2025 £000 | |
| Investment income: | ||
| Dividends from unquoted companies | 125 | 23 |
| Dividends from quoted companies | 132 | 304 |
| Money market funds* | 1,146 | 1,123 |
| Bank deposits* | 212 | 352 |
| Loans to unquoted companies | 238 | 890 |
| 1,853 | 2,692 |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| Basic investment management fee | 634 | 1,903 | 2,537 | 582 | 1,745 | 2,327 |
| Performance-related fee | – | – | – | – | 65 | 65 |
| 634 | 1,903 | 2,537 | 582 | 1,810 | 2,392 |
| Year ended 31 March 2026 £000 | Year ended 31 March 2025 £000 | |
| Administrative and secretarial services | 74 | 72 |
| Directors’ remuneration | 161 | 134 |
| National Insurance contributions | 19 | 12 |
| Auditor’s remuneration – audit services | 73 | 76 |
| – non-audit services | – | – |
| Legal and professional expenses | 46 | 36 |
| Share issue promoter’s commission | 27 | 30 |
| Other expenses | 178 | 185 |
| 578 | 545 |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| (a) Analysis of charge/(credit) for the year | ||||||
| UK corporation tax payable/(recoverable) on the return for the year | 96 | (96) | – | 585 | (585) | – |
| (b) Tax reconciliation | ||||||
| Return before tax | 641 | (1,593) | (952) | 1,565 | 5,391 | 6,956 |
| Return multiplied by the standard rate of UK corporation tax of 25.0% (2025: 25.0%) | 160 | (398) | (238) | 391 | 1,348 | 1,739 |
| Effect of: | ||||||
| Dividends not subject to tax | (64) | – | (64) | (82) | – | (82) |
| Capital returns not subject to tax | – | (76) | (76) | – | (726) | (726) |
| Movements in fair value of investments not subject to tax | – | (2) | (2) | – | (1,075) | (1,075) |
| Increase in surplus management expenses | – | 380 | 380 | – | 144 | 144 |
| Adjustment in respect of previous year | – | – | – | 276 | (276) | – |
| Tax charge/(credit) for the year | 96 | (96) | – | 585 | (585) | – |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| (a) Recognised as distributions in the financial statements for the year | ||||||
| Previous year’s final dividend | 447 | 3,276 | 3,723 | 736 | 2,502 | 3,238 |
| Current year’s first interim dividend | 159 | 3,020 | 3,179 | 437 | 2,478 | 2,915 |
| 606 | 6,296 | 6,902 | 1,173 | 4,980 | 6,153 | |
| (b) Paid and proposed in respect of the year | ||||||
| Interim paid – 2.0p (2025: 2.0p) per share | 159 | 3,020 | 3,179 | 437 | 2,478 | 2,915 |
| Final proposed – 2.5p (2025: 2.5p) per share | 473 | 3,468 | 3,941 | 434 | 3,179 | 3,613 |
| 632 | 6,488 | 7,120 | 871 | 5,657 | 6,528 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Level 1 | ||
| Quoted venture capital investments | 5,907 | 3,490 |
| Listed equity investment funds | – | 12,112 |
| Level 3 | ||
| Unquoted venture capital investments | 93,438 | 87,629 |
| 99,345 | 103,231 |
| Venture capital – unquoted Level 3 £000 | Venture capital – quoted Level 1 £000 | Listed equity Level 1 £000 | Total £000 | |
| Book cost at 31 March 2025 | 82,582 | 2,223 | 10,794 | 95,599 |
| Fair value adjustment at 31 March 2025 | 5,047 | 1,267 | 1,318 | 7,632 |
| Fair value at 31 March 2025 | 87,629 | 3,490 | 12,112 | 103,231 |
| Movements in the year: | ||||
| Purchases at cost | 15,821 | – | 204 | 16,025 |
| Transfer on market listing* | (6,382) | 6,382 | – | |
| Disposals – proceeds | (2,235) | (5,375) | (12,611) | (20,221) |
| – net realised gains on disposal | (941) | 950 | 295 | 304 |
| Movements in fair value | (454) | 460 | – | 6 |
| Fair value at 31 March 2026 | 93,438 | 5,907 | – | 99,345 |
| Comprising: | ||||
| Book cost at 31 March 2026 | 86,968 | 2,539 | – | 89,507 |
| Fair value adjustment at 31 March 2026 | 6,470 | 3,368 | – | 9,838 |
| 93,438 | 5,907 | – | 99,345 | |
| Equity shares | 79,073 | 5,907 | – | 84,980 |
| Preference shares | 2,527 | – | – | 2,527 |
| Interest-bearing securities | 11,838 | – | – | 11,838 |
| 93,438 | 5,907 | – | 99,345 |
| Valuation methodology | 31 March 2026 £000 | 31 March 2025 £000 |
| Revenue multiple | 63,138 | 54,473 |
| Cost and price of recent investment (calibrated and reviewed for impairment) | 26,215 | 20,514 |
| Earnings multiple | 4,085 | 12,612 |
| Net assets | – | 30 |
| 93,438 | 87,629 |
| Valuation technique | Fair value £000 | Multiple range | Weighted average multiple | Change in input | Change in fair value of investments £000 | Change in NAV (pence per share) |
| Revenue multiple | 63,138 | 0.1x – 8.0x | 3.3x | + 10% | 3,913 | 2.48 |
| -10% | (3,003) | (1.90) | ||||
| Earnings multiple | 4,085 | 2.5x – 9.2x | 5.8x | + 10% | 652 | 0.41 |
| -10% | (551) | (0.35) |
| Valuation technique | Fair value £000 | Multiple range | Weighted average multiple | Change in input | Change in fair value of investments £000 | Change in NAV (pence per share) |
| Revenue multiple | 54,473 | 0.25x – 8.0x | 4.5x | + 10% | 3,700 | 2.56 |
| -10% | (2,476) | (1.71) | ||||
| Earnings multiple | 12,612 | 4.0x – 8.0x | 7.0x | + 10% | 1,280 | 0.89 |
| -10% | (1,416) | (0.98) |
| Original cost £000 | Carrying value at 31 March 2025 £000 | Purchases in year £’000 | Disposal proceeds £000 | Realised gain/(loss) against carrying value £000 | |
| Idox plc – disposal of entire holding | 530 | 2,492 | – | 3,087 | 595 |
| The Beauty Tech Group – partial disposal | 609 | 2,133 | – | 2,495 | 362 |
| Thanksbox (t/a Mo) – disposal of entire holding | 1,520 | 363 | – | 818 | 455 |
| Fresh Approach (UK) Holdings – disposal of entire holding | 771 | 273 | – | 768 | 495 |
| Buoyant Upholstery – partial disposal | 387 | 387 | – | 387 | – |
| Intuitive Holding – deferred proceeds | – | – | – | 44 | 44 |
| CelLBxHealth (formerly Angle) – partial disposal | 65 | 18 | – | 11 | (7) |
| Adludio – in liquidation | 2,714 | 31 | – | – | (31) |
| Northrow – in administration | 1,385 | 69 | – | – | (69) |
| Newcells Biotech – in administration | 3,136 | 1,598 | 237 | – | (1,835) |
| 11,117 | 7,364 | 237 | 7,610 | 9 |
| Company | Registered office address | Investment type | Equity held % | Equity £000 | Debt £000 | Total investment cost £000 |
| Biological Preparations Group | Unit 12 A-C Pantglas Industrial Estate, Bedwas, Caerphilly CF83 8DR | Unquoted | 21 | 504 | 1,411 | 1,915 |
| Volumatic Holdings | Taurus House, Endemere Road, Coventry CV6 5PY | Unquoted | 25 | 216 | – | 216 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Accrued income | 101 | 115 |
| Due from investment sales | 44 | 2,148 |
| Prepayments | 29 | 32 |
| 174 | 2,295 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Cash at bank | 7,858 | 7,862 |
| Money market funds | 27,000 | 17,000 |
| 34,858 | 24,862 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Accruals and deferred income | 196 | 279 |
| 196 | 279 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Allotted and fully paid: | ||
| 157,645,007 (2025: 144,514,326) ordinary shares of 5.0p | 7,882 | 7,226 |
| Share premium £000 | Capital redemption reserve £000 | Capital reserve £000 | Revaluation reserve £000 | Revenue reserve £000 | |
| At 31 March 2025 | 62,268 | 1,192 | 50,538 | 7,632 | 1,253 |
| Premium on issue of ordinary shares | 17,534 | – | – | – | – |
| Share issue expenses | (604) | – | – | – | – |
| Shares purchased for cancellation | – | 355 | (6,015) | – | – |
| Realised on disposal of investments | – | – | 304 | – | – |
| Transfer on disposal of investments | – | – | (2,200) | 2,200 | – |
| Movements in fair value of investments | – | – | – | 6 | – |
| Management fee charged to capital net of associated tax | – | – | (1,807) | – | – |
| Revenue return after tax | – | – | – | – | 545 |
| Dividends recognised in the year | – | – | (6,296) | – | (606) |
| At 31 March 2026 | 79,198 | 1,547 | 34,524 | 9,838 | 1,192 |
| 31 March 2026 | 31 March 2025 | |||||
| Total fixed rate portfolio £000 | Weighted average interest rate % | Weighted average period for which rate is fixed Years | Total fixed rate portfolio £000 | Weighted average interest rate % | Weighted average period for which rate is fixed Years | |
| Fixed-rate investments in unquoted companies | 11,838 | 9.6% | 2.5 | 9,788 | 10.4% | 1.9 |
| 31 March 2026 | 31 March 2025 | |
| £000 | £000 | |
| Cash and cash equivalents | 34,858 | 24,862 |
| 34,858 | 24,862 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Fixed-rate investments in unquoted companies (above) | 11,838 | 9,788 |
| Cash and cash equivalents | 34.858 | 24,862 |
| Accrued dividends and interest receivable | 101 | 115 |
| 46.797 | 34,765 |